Comparison between Rednex Pharmaceuticals IPO and Vinod Texworld IPO.
Rednex Pharmaceuticals IPO is a SME Fixed Price IPO proposed to list at BSE SME while Vinod Texworld IPO is a SME Fixed Price proposed to list at NSE SME.
The total issue size of Rednex Pharmaceuticals IPO is up to ₹0.00 Cr whereas the issue size of the Vinod Texworld IPO is up to ₹0.00 Cr. The final issue price of Rednex Pharmaceuticals IPO is and of Vinod Texworld IPO is .
| Rednex Pharmaceuticals IPO | Vinod Texworld IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 27,36,000 shares | 45,56,800 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 27,36,000 shares | 45,56,800 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
Rednex Pharmaceuticals IPO opens on , while Vinod Texworld IPO opens on . The closing date of Rednex Pharmaceuticals IPO and Vinod Texworld IPO is , and , respectively.
Rednex Pharmaceuticals IPO P/E ratio is , as compared to Vinod Texworld IPO P/E ratio of .
| Rednex Pharmaceuticals IPO | Vinod Texworld IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Rednex Pharmaceuticals Ltd.'s revenue increased by 88% and profit after tax (PAT) rose by 120% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Vinod Texworld Ltd.'s revenue increased by 24% and profit after tax (PAT) rose by 74% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 93.10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 58.10 | 28.79 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 23.29 | 34.99 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.94 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 45.02 | 28.79 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Rednex Pharmaceuticals IPO Retail Individual Investors (RII) are offered 0 shares while in Vinod Texworld IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Rednex Pharmaceuticals IPO and 0 shares in Vinod Texworld IPO.
| Rednex Pharmaceuticals IPO | Vinod Texworld IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Rednex Pharmaceuticals IPO subscribed in total, whereas Vinod Texworld IPO subscribed .
